Neuropsychological and morphometric biomarkers of poor prognosis in patients with mild cognitive impairment

Despite a high prevalence of mild cognitive impairment (MCI), there are no accepted algorithms of diff erentiating the syndrome and the prognosis evaluation of later cognitive decline at this time. Objective. To identify biomarkers of poor prognosis in the various MCI types by optimizing neuropsychological examination in combination with MRI morphometry of brain structures. Patients and methods. We examined 45 patients (9 men, 36 women, mean age 72 ± 6.7 years) with MCI according to the modifi ed Petersen’s criteria and the DSM-5 criteria. All patients underwent the MMSE scale, the Detailed Neuropsychological Testing (DNT), which included a Ten Words Test (TWT), a “Double Test” (DT), a visual acuity test, a high-fi eld magnetic resonance imaging (MRI) of the brain with morphometry of cerebral structures (FreeSurfer, FSL). Results. According to the MMSE score, MCI were found in 26 (58%) patients. During the DNT, depending on the state of memory, 14 participants of the study identifi ed a non-amnestic type of MCI (na-MCI), 15 — an amnestic variant with impaired reproduction (ar-MCI), and 16 people — an amnestic type with a primary memory defect (apm-MCI). Volume changes of the anterior corpus callosum segment (CCA) were signifi cantly associated with the Immediate Recall after 4th reading and the Delayed Recall in the general MCI group (rho = 0.58; 0.58; p < 0.05) and the apmMCI group (rho = 0.6; 0.56; p < 0.05). Kruskal–Wallis Test showed that there were signifi cant group diff erences in the volumes of the CCA, right caudate nucleus, left cerebellar hemisphere cortex, posterior corpus callosum segment and left thalamus. At the same time, the fi rst three structures were combined into a set of informative features for differentiating the type of MCI based on the results of Forward stepwise Discriminant Analysis with a 77.3% accurate classifi cation rate (Wilks’s Lambda: 0.35962; approx. F (6.78) = 8.678, p < 0.001). ROC-analysis established the threshold values of the CCA volumes of ≤ 0.05% and the right caudate nucleus volumes of ≤ 0.23% (81.25% sensitivity in both cases; 62.1% and 60.7% specifi city; AUC 0.787 and 0.767; 95% CI 0.639–0.865 and 0.615–0.881; OR 7.1 and 6.7 (95% CI 1.6–30.6 and 1.6–29), associated with a memory defect in persons with MCI, while the ORs are 7.1 and 6.7 (95% CI 1.6–30.6 and 1.6–29), respectively. When both cerebral structures were included in the logit model, 88.6% classifi cation accuracy, 92.6% sensitivity, and 82.4% specifi city of the method were achieved. Conclusion. It has been demonstrated that classifying patients into the various types of MCI based on the data of memory function refl ected by the DNT and supplemented with MRI morphometry of the brain areas may be used as a sensitive and specifi c instrument for determining the category of patients with a high risk of Alzheimer’s disease. A neuropsychological profi le with a defect in primary memory, atrophic changes in anterior segment of the corpus callosum and the right caudate nucleus have been proposed as biomarkers of poor prognosis. Further longitudinal studies are necessary to clarify the proposed biomarkers of poor prognosis information and to detail the mechanisms of the neurodegenerative process.

Survival in patients with radiological diagnoses of glioblastoma: a retrospective study of 115 patients on a best supportive care pathway

Aims Glioblastoma multiforme (GBM) is a devastating disease with notoriously poor survival. Studies examining survival in patients given best supportive care (BSC) are few and far between. All patients harbouring brain tumours referred to the Neuro-oncology service at the Queen Elizabeth Hospital in Birmingham are recorded in the Somerset Cancer Registry. We set out to analyse survival times and identify patient and tumour-related factors significantly affecting prognosis. Method We identified 126 patients from 2015 to 2019 in our Somerset Cancer Registry with radiological diagnoses of glioblastoma for whom the Neuro-oncology MDT recommended BSC. We performed a retrospective analysis of clinical records and radiological images. 11 patients were excluded (8 due to insufficient imaging data, 2 who underwent subsequent surgery, 1 patient with brain metastases). Survival was measured in completed weeks since the index MDT decision. Associations between survival time and both patient- and tumour-related factors were assessed using Kaplan-Meier curves and log-rank tests. All analyses were performed using IBM SPSS 22 (IBM Corp. Armonk, NY), with p&lt;0.05 deemed to be indicative of statistical significance throughout. Results Data were available for N=115 patients (69 males, 46 females), with a mean age of 79 ± 8 years. All patients died within 32 weeks of diagnosis, with a median survival time of 8 weeks. Only 8 patients survived for more than 20 weeks. Survival was significantly shorter in those with a greater number of main cerebral structures affected (p=0.044), with a median of 6 vs. 10 weeks for 3 or more vs. 1 structures affected (hazard ratio: 1.61, 95% CI: 0.99-2.62). Bilateral tumours involving the corpus callosum were also associated with shorter survival (p=0.039). None of the other factors considered were found to be significantly associated with survival, including age (p=0.193), gender (p=0.371), performance status (p=0.300) and tumour size (p=0.331). Conclusion With the exception of the number of main cerebral structures affected (frontal, parietal, temporal and occipital lobes, corpus callosum, insula, basal ganglia and brain stem), patient- and tumour-factors traditionally used by the MDT to prognosticate do not correlate with survival time in patients receiving BSC for radiological diagnoses of GBM. With 50% of the cohort dying within 8 weeks it is clear that we must reconsider the timing of referrals to palliative and hospice care. Finally, the fact that some patients survived for more than half a year with no surgical or oncological treatment suggests that the process of selecting patients for BSC vs aggressive treatments needs refinement.

Patterns of Brain Injury in Perinatal Arterial Ischemic Stroke and the Development of Infantile Spasms

Introduction: Perinatal arterial ischemic stroke (PAIS) underlies approximately 10% of infantile spasms (IS). We aim to identify patterns of brain injury in ischemic stroke that may predispose infants to infantile spasms. Methods: Sixty-four perinatal arterial ischemic stroke patients were identified meeting the following inclusion criteria: term birth, magnetic resonance imaging (MRI) showing ischemic stroke or encephalomalacia in an arterial distribution, and follow-up records. Patients who developed infantile spasms (PAIS-IS) were analyzed descriptively for ischemic stroke injury patterns and were compared to a seizure-free control group (PAIS-only). Stroke injury was scored using the modified pediatric ASPECTS (modASPECTS). Results: The PAIS-IS (n = 9) group had significantly higher modASPECTS than the PAIS-only (n = 16) group ( P = .002, Mann-Whitney). A greater proportion of PAIS-IS patients had injury to deep cerebral structures (67%) than PAIS-only (25%). Conclusion: Infarct size was significantly associated with infantile spasms development. Results support theories implicating deep cerebral structures in infantile spasms pathogenesis. This may help identify perinatal arterial ischemic stroke patients at risk of infantile spasms, facilitating more timely diagnosis.

Aquaporins and Roles in Brain Health and Brain Injury

In the literature screening, aquaporins were found in the cerebral structures including the pia mater, choroid plexus, ependyma, piriform cortex, hippocampus, dorsal thalamus, supraoptic and suprachiasmatic nuclei, white matter and subcortical organ. Among these, the most common are AQP1, AQP4, and AQP9. The roles of aquaporins have been demonstrated in several diseases such as cerebral edema, various central nervous system tumors, Alzheimer’s Disease and epilepsy. In this review, the relationship between brain/brain-injury and aquaporin, has been reviewed.

Therapeutic potential of selanyl amide derivatives in the in vitro anticholinesterase activity and in in vivo antiamnesic action

The present study evaluated the in vitro acetylcholinesterase (AChE) inhibitor activity of two new selanyl amide derivatives in cerebral structures of mice. Our results demonstrated that N-(2-(3-(phenylselanyl)propoxy)phenyl)furan-2-carboxamide (1) and N-(2-(3-(phenylselanyl)propoxy)phenyl)thiophene-2-carboxamide (2) inhibited the in vitro AChE activity in mice. Another objective was to assess the effect of the best AChE inhibitor in an amnesic model induced by scopolamine (SCO) in male Swiss mice. The involvement of AChE activity and lipid peroxidation in the cerebral structures was investigated. Our results showed that compound 1 (10 mg/kg, intragastrically) attenuated the latency to find the escape box and the number of holes visited in the Barnes maze task, without altering the locomotor and exploratory activities in an open-field test. Compound 1 protected against increasing in lipid peroxidation levels and AChE activity caused by SCO in the cerebral cortex and hippocampus of mice. In conclusion, the present study evidenced the in vitro anticholinesterase effect of two new selanyl amide derivatives in the cerebral structures of mice. Moreover, compound 1, a selanyl amide derivative containing a furan ring, demonstrated antiamnesic action due to its antioxidant and anticholinesterase activities in cerebral structures.

Coadministration of lithium and celecoxib reverses manic-like behavior and decreases oxidative stress in a dopaminergic model of mania induced in rats

The present study intends to investigate the effect of lithium (Li) and celecoxib (Cel) coadministration on the behavioral status and oxidative stress parameters in a rat model of mania induced by dextroamphetamine (d-AMPH). Male Wistar rats were treated with d-AMPH or saline (Sal) for 14 days; on the 8th day of treatment, rats received lithium (Li), celecoxib (Cel), Li plus Cel, or water until day 14. Levels of oxidative stress parameters were evaluated in the serum, frontal cortex, and hippocampus. d-AMPH administration induced hyperlocomotion in rats, which was significantly reversed by Li and Cel coadministration. In addition, d-AMPH administration induced damage to proteins and lipids in the frontal cortex and hippocampus of rats. All these impairments were reversed by treatment with Li and/or Cel, in a way dependent on cerebral area and biochemical analysis. Li and Cel coadministration reversed the d-AMPH-induced decrease in catalase activity in cerebral structures. The activity of glutathione peroxidase was decreased in the frontal cortex of animals receiving d-AMPH, and treatment with Li, Cel, or a combination thereof reversed this alteration in this structure. Overall, data indicate hyperlocomotion and alteration in oxidative stress biomarkers in the cerebral structures of rats receiving d-AMPH. Li and Cel coadministration can mitigate these modifications, comprising a potential novel approach for BD therapy.

Monocular Vision Loss: A Rare Cause

A 62-year-old woman with a history of metastatic breast cancer and known meningioma presented with unilateral vision loss associated with anisocoria and an afferent pupillary defect. On magnetic resonance imaging we found the cause to be optic nerve compression by a right frontal meningioma. Monocular vision-loss etiologies are anatomically localized to structures anterior to the optic chiasm. This case serves as a reminder that cerebral structures in this location must not be forgotten in the differential.